Jinghua Pharmaceutical announced on October 11 that it recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving clinical trials for Ji Desheng Sheyao Tablets to add a new indication for shingles, specifically the liver-gallbladder damp-heat syndrome. The application was accepted on July 17, 2026, and the review conclusion agreed to conduct the relevant clinical trials, with the approval date being October 8, 2026. Ji Desheng Sheyao Tablets are already on the market, with current approved functions of clearing heat, detoxifying, reducing swelling, and relieving pain, used for venomous snake and insect bites. The clinical trials for this new indication will proceed with Phase II and Phase III trials according to the general principles of drug development to verify its clinical value. The company stated that this approval will not have a significant impact on current operating performance, but drug development is characterized by high investment, long cycles, and high risk, and future market competition and research outcomes remain uncertain. In the first half of 2026, Jinghua Pharmaceutical achieved revenue of 755 million yuan and net profit attributable to the parent company of 136 million yuan.
Nantong Jinghua Pharmaceutical Co LtdReceived NMPA clinical trial approval to add a new shingles indication for Ji Desheng Sheyao Tablets, advancing its R&D pipeline.
